Skip to main content
Retour
AMGN logo

Amgen Inc.

Qualité des données : 100%
AMGN
NASDAQ Healthcare Drug Manufacturers - General
349,77 €
▲ 1,97 € (0,57%)
Cap. Boursière : 188,55B
Fourchette du Jour
348,61 € 353,42 €
Fourchette 52 Semaines
261,43 € 391,29 €
Volume
2 218 975
Moyenne 50J / 200J
359,42 € / 316,58 €
Clôture Précédente
347,80 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 24,5 0,4
P/B 21,8 2,9
ROE % 106,1 3,7
Net Margin % 21,0 3,8
Rev Growth 5Y % 9,1 10,0
D/E 6,3 0,2

Insider Trading Activity

Buy ratio (90d) 0.0%
20 transactions
Date Insider Type Shares Price Value
Mar 16, 2026
Graham Jonathan P
EVP & Gen. Counsel & Sec.
other 5 353 366,21 € 1 960 322 €
Mar 16, 2026
Miller Derek
SVP, Human Resources
other 1 616 366,21 € 591 795 €
Mar 16, 2026
Gordon Murdo
EVP, Global Commercial Ops
other 6 691 366,21 € 2 450 311 €
Mar 16, 2026
Santos Esteban
EVP, Operations
other 5 621 366,21 € 2 058 466 €
Mar 3, 2026
Khosla Rachna
SVP, Business Development
grant 1 876
Mar 3, 2026
Miller Derek
SVP, Human Resources
grant 3 484
Mar 3, 2026
Grygiel Nancy A.
SVP & CCO
grant 2 010
Mar 3, 2026
REESE DAVID M
EVP & Chief Technology Officer
grant 12 063
Feb 19, 2026
Busch Matthew C.
VP, Finance & CAO
sell 1 000 375,79 € 375 790 €
Nov 12, 2025
Khosla Rachna
SVP, Business Development
sell 890 336,24 € 299 256 €
Aug 8, 2025
ISHRAK OMAR
Director
grant 121
Aug 8, 2025
HOLLEY CHARLES M
Director
grant 147
May 23, 2025
Garland Greg C.
Director
grant 809
May 23, 2025
Austin Wanda M
Director
grant 809
May 23, 2025
ECKERT ROBERT
Director
grant 809
May 23, 2025
Jacks Tyler
Director
grant 809
May 6, 2025
Busch Matthew C.
VP, Finance & CAO
grant 4 139
May 6, 2025
ISHRAK OMAR
Director
grant 129
May 2, 2025
Grygiel Nancy A.
SVP & CCO
other 229 283,78 € 64 986 €
May 2, 2025
Miller Derek
SVP, Human Resources
other 349 283,78 € 99 039 €

Points Clés

Revenue grew 9,05% annually over 5 years — modest growth
Earnings grew 88,53% over the past year
ROE of 106,10% indicates high profitability
Net margin of 20,99% shows strong profitability
Debt/Equity of 6,31 — high leverage
Generating 8,10B in free cash flow

Croissance

Revenue Growth (5Y)
9,05%
Revenue (1Y)9,92%
Earnings (1Y)88,53%
FCF Growth (3Y)4,91%

Qualité

Return on Equity
106,10%
ROIC12,66%
Net Margin20,99%
Op. Margin29,06%

Sécurité

Debt / Equity
6,31
Current Ratio1,14
Interest Coverage3,88

Valorisation

P/E Ratio
24,45
P/B Ratio21,78
EV/EBITDA21,92
Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 9,92% Revenue Growth (3Y) 14,16%
Earnings Growth (1Y) 88,53% Earnings Growth (3Y) 7,14%
Revenue Growth (5Y) 9,05% Earnings Growth (5Y) 6,95%
Profitability
Revenue (TTM) 36,74B Net Income (TTM) 7,71B
ROE 106,10% ROA 8,51%
Gross Margin 70,80% Operating Margin 29,06%
Net Margin 20,99% Free Cash Flow (TTM) 8,10B
ROIC 12,66% FCF Growth (3Y) 4,91%
Safety
Debt / Equity 6,31 Current Ratio 1,14
Interest Coverage 3,88 Dividend Yield 0,03%
Valuation
P/E Ratio 24,45 P/B Ratio 21,78
P/S Ratio 5,13 PEG Ratio 0,26
EV/EBITDA 21,92 Dividend Yield 0,03%
Market Cap 188,55B Enterprise Value 234,02B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 36,74B 33,42B 28,19B 26,32B 25,98B
Net Income 7,71B 4,09B 6,72B 6,55B 5,89B
EPS (Diluted) 14,23 7,56 12,49 12,11 10,28
Gross Profit 26,01B 20,57B 19,78B 19,92B 19,53B
Operating Income 10,68B 7,26B 7,90B 9,57B 7,64B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 90,59B 91,84B 97,15B 65,12B 61,17B
Total Liabilities 81,93B 85,96B 90,92B 61,46B 54,47B
Shareholders' Equity 8,66B 5,88B 6,23B 3,66B 6,70B
Total Debt 54,60B 60,10B 64,61B 38,95B 33,31B
Cash & Equivalents 9,13B 11,97B 10,94B 7,63B 7,99B
Current Assets 29,06B 29,03B 30,33B 22,19B 19,39B
Current Liabilities 25,49B 23,10B 18,39B 15,69B 12,18B

Scores de Stratégies

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
#84 of 213
46
#87 of 326
62

Activité Récente

Entré Capital Light Compounder
Mar 24, 2026
Entré Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026